International Multicenter Retrospective Study of Spindle Cell/Sclerosing Rhabdomyosarcoma: A PUSH Consortium Study
We report clinical outcomes of patients with localized and advanced spindle cell/sclerosing rhabdomyosarcoma (S-RMS) from the Pushing Ultra-Rare Sarcomas Towards Hope (PUSH) consortium, an international collaborative network. Clinical data from patients with molecularly confirmed S-RMS treated at 25 institutions between January 2013 and December 2023 were reviewed. Endpoints included overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), and overall response rate (ORR). Univariate analyses were performed. Sixty-four patients were identified. The most common molecular alteration was MYOD1 p.L122R mutation (56%). Among patients with localized S-RMS (n=42), the 3-year OS and DFS rates were 61.2% and 34.2%, respectively. Local recurrence was more frequent than distant metastasis (14 vs. 8). Tumor size was significantly associated with DFS (P=0.008) and distant metastasis (P=0.012). Among patients with advanced S-RMS (n=37), median OS was 14.8 months (95% CI: 10.1-28.0), with 26.2% alive at 2 years. Lung metastasis was associated with worse OS (HR=4.07, P=0.004). Twenty-nine patients (78%) received first-line chemotherapy, most commonly anthracycline-based treatment (48%). The median PFS was 5.4 months (95% CI: 3.7-12.0), and evaluable ORR was 24% (6/25). The evaluable ORR was 27% in MYOD1-altered and 22% in TFCP2-altered patients across all treatment lines. These findings suggest that ∼one-third of patients with completely resected localized S-RMS may be cured. The predominance of local recurrence highlights the need to optimize locoregional management. Advanced S-RMS has a poor prognosis, and conventional systemic therapies provide limited benefit, underscoring the urgent need for novel treatments.
Authors
- Andrea Napolitano (ORCID: https://orcid.org/0000-0002-7509-1555)
- Daniel Wong (ORCID: https://orcid.org/0000-0001-5069-1557)
- Anna Mariuk-Jarema (ORCID: https://orcid.org/0000-0002-4237-1139)
- Ryan A. Denu (ORCID: https://orcid.org/0000-0001-9698-9201)
- Ruben Jaeger
- Daniel S. Lefler (ORCID: https://orcid.org/0000-0001-8051-8800)
- Silva Ljevar (ORCID: https://orcid.org/0000-0002-1151-1477)
- Angelo Paolo Dei Tos (ORCID: https://orcid.org/0000-0002-1228-8940)
- Ilkyu Han (ORCID: https://orcid.org/0000-0001-9841-3775)
- Gabriel Tinoco (ORCID: https://orcid.org/0000-0002-2565-6124)
- Jessica L. Davis (ORCID: https://orcid.org/0000-0002-2725-1518)
- William Tap
- Rosalba Miceli (ORCID: https://orcid.org/0000-0003-0954-375X)
- Ingrid M.E. Desar (ORCID: https://orcid.org/0000-0003-0945-8299)
- Roberto Scanferla (ORCID: https://orcid.org/0000-0002-4271-8278)
- Alexander J. Lazar (ORCID: https://orcid.org/0000-0002-6395-4499)
- Vivek A. Bhadri (ORCID: https://orcid.org/0000-0002-9814-2060)
- Lorenzo D’Ambrosio (ORCID: https://orcid.org/0000-0003-3294-8819)
- Tom Wei‐Wu Chen (ORCID: https://orcid.org/0000-0003-4112-4029)
- Silvia Stacchiotti (ORCID: https://orcid.org/0000-0002-1742-8666)
- Claudia Giani (ORCID: https://orcid.org/0000-0001-8630-4037)
- Giacomo Giulio Baldi (ORCID: https://orcid.org/0000-0003-0798-7752)
- Philippos Apolinário Costa (ORCID: https://orcid.org/0000-0001-9681-0515)
- Silvia Taverna
- Daniel Jack Reinhorn (ORCID: https://orcid.org/0000-0002-7717-9032)
- Marta Sbaraglia (ORCID: https://orcid.org/0000-0002-7116-6513)
- Valerie Shiwen Yang (ORCID: https://orcid.org/0000-0002-8844-9421)
- Susie Bae (ORCID: https://orcid.org/0000-0002-4514-4142)
- Judith V.M.G. Bovée (ORCID: https://orcid.org/0000-0003-1155-0481)
- Michael S. Nakazawa (ORCID: https://orcid.org/0000-0002-6272-5467)
- Cristina R. Antonescu (ORCID: https://orcid.org/0000-0002-9717-8205)
- Inga‐Marie Schaefer (ORCID: https://orcid.org/0000-0001-9710-5500)
- Boris Itkin (ORCID: https://orcid.org/0000-0001-8837-8427)
- Miguel Henriques Abreu
- Elizabeth M. Connolly
- Xiaolan Feng
- Toni Ibrahim
- Alessandro Gronchi
- Ana Sebio
- Mauricio F. Ribeiro
- Ajay Gupta
Institutions
- Brigham and Women's Hospital (US)
- Roswell Park Comprehensive Cancer Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- University of Padua (IT)
- University of Calgary (CA)
- The University of Western Australia (AU)
- Leiden University Medical Center (NL)
- Peter MacCallum Cancer Centre (AU)
- Hospital de Sant Pau (ES)
- Seoul National University Hospital (KR)
- Radboud University Medical Center (NL)
- The Netherlands Cancer Institute (NL)
- Moffitt Cancer Center (US)
- Yale University (US)
- Queen Elizabeth II Medical Centre (AU)
- Chris O’Brien Lifehouse (AU)
- University Hospital of Zurich (CH)
- Cancer Research And Biostatistics (US)
- IPO Porto (PT)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Royal Marsden Hospital (GB)
- Istituto Ortopedico Rizzoli (IT)
- National Taiwan University Hospital (TW)
- National Cancer Centre Singapore (SG)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- Center for Clinical Research (United States) (US)
- Azienda Usl Toscana Centro (IT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Pathwest Laboratory Medicine (AU)
- Hospital of Prato (IT)
- Indiana University School of Medicine (US)
- Sultan Qaboos Comprehensive Cancer Care & Research Center (OM)
- Sultan Qaboos University (OM)
- The Ohio State University (US)
- University of Turin (IT)
- University of Pennsylvania (US)
Publication Details
- Journal
- The American Journal of Surgical Pathology
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1097/pas.0000000000002639
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00